At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 197 enrolled
Drug / intervention
rizatriptan +1 moredrug
Likely dose
rizatriptan 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observer-Blind, Randomized, Parallel-Group Study to Compare the Efficacy of Two Rizatriptan Prescribing Portions for the Treatment of Migraine
In Brief
A Phase 4 clinical trial evaluating rizatriptan for Migraine. Completed, enrolled 197 participants across 10 sites.
Detailed Summary
The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2006
Enrollment StartDec 2006
Primary CompletionJan 2008
TodayJul 2026
First PostedNov 9, 2006
Enrollment StartDec 1, 2006
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 19.6 years ago
Interventions
rizatriptandrug
10mg ODT 27 tablets
rizatriptandrug
10mg ODT 9 tablets